

Antisense Therapeutics Ltd (ANP) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/AAD263A3059EN.html

Date: October 2021 Pages: 41 Price: US\$ 125.00 (Single User License) ID: AAD263A3059EN

Abstracts

Antisense Therapeutics Ltd (ANP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.



Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Antisense Therapeutics Ltd (Antisense Therapeutics) is clinical staged biopharmaceutical company which focuses on the discovery, development and commercialization of second-generation antisense pharmaceuticals for various medical conditions that have large unmet medical needs. It focuses on the development of antisense drugs in the areas of immunology disorders and rare diseases such as multiple sclerosis (MS) among others. Antisense Therapeutics's development pipeline comprises of ATL1103 for potential treatment for growth hormone disorders such as Acromegaly; ATL1102 (injection), which reduces brain lesions is being development for the treatment of multiple sclerosis. ATL1102 is also being developed for the treatment of duchenne muscular dystrophy (DMD). Antisense Therapeutics is headquartered in Toorak, Victoria, Australia.

Antisense Therapeutics Ltd Key Recent Developments

Aug 24,2021: ANP to participate in PPMD development of new Community-Led Duchenne Guidance for FDA Jul 29,2021: Antisense Therapeutics: Quarterly activities report & appendix 4C Jul 28,2021: Antisense Therapeutics transitions to new Board Chair



Mar 22,2021: Antisense Therapeutics appoints new Non-executive Director Apr 21,2020: Antisense Therapeutics: Quarterly Update & Appendix 4C

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.



Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contents

SECTION 1 - ABOUT THE COMPANY

Antisense Therapeutics Ltd - Key Facts Antisense Therapeutics Ltd - Key Employees Antisense Therapeutics Ltd - Key Employee Biographies Antisense Therapeutics Ltd - Major Products and Services Antisense Therapeutics Ltd - History Antisense Therapeutics Ltd - Locations And Subsidiaries Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview Antisense Therapeutics Ltd - Business Description Antisense Therapeutics Ltd - Corporate Strategy Antisense Therapeutics Ltd - SWOT Analysis SWOT Analysis - Overview Antisense Therapeutics Ltd - Strengths Antisense Therapeutics Ltd - Weaknesses Antisense Therapeutics Ltd - Opportunities Antisense Therapeutics Ltd - Threats Antisense Therapeutics Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios Financial Ratios - Annual Ratios Performance Chart Financial Performance Financial Ratios - Interim Ratios Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021 Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to



YTD 2021

Antisense Therapeutics Ltd, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Aug 24, 2021: ANP to participate in PPMD development of new Community-Led Duchenne Guidance for FDA Jul 29, 2021: Antisense Therapeutics: Quarterly activities report & appendix 4C Jul 28, 2021: Antisense Therapeutics transitions to new Board Chair Mar 22, 2021: Antisense Therapeutics appoints new Non-executive Director Apr 21, 2020: Antisense Therapeutics: Quarterly Update & Appendix 4C Feb 27, 2020: Antisense Therapeutics announces appointment of US-based consultant medical director

SECTION 6 – APPENDIX

Methodology Ratio Definitions About GlobalData Contact Us Disclaimer



List Of Tables

LIST OF TABLES

Antisense Therapeutics Ltd, Key Facts Antisense Therapeutics Ltd, Key Employees Antisense Therapeutics Ltd, Key Employee Biographies Antisense Therapeutics Ltd, Major Products and Services Antisense Therapeutics Ltd, History Antisense Therapeutics Ltd, Key Competitors Antisense Therapeutics Ltd, Ratios based on current share price Antisense Therapeutics Ltd, Annual Ratios Antisense Therapeutics Ltd, Annual Ratios (Cont...1) Antisense Therapeutics Ltd, Interim Ratios Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021 Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021 Antisense Therapeutics Ltd, Recent Deals Summary **Currency Codes Capital Market Ratios** Equity Ratios **Profitability Ratios** Cost Ratios Liquidity Ratios Leverage Ratios **Efficiency Ratios**



List Of Figures

LIST OF FIGURES

Antisense Therapeutics Ltd, Performance Chart (2017 - 2021) Antisense Therapeutics Ltd, Ratio Charts Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021 Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



I would like to order

Product name: Antisense Therapeutics Ltd (ANP) - Financial and Strategic SWOT Analysis Review Product link: <u>https://marketpublishers.com/r/AAD263A3059EN.html</u>

Price: US\$ 125.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/AAD263A3059EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970